Free Trial
NASDAQ:HURA

TuHURA Biosciences 9/18/2023 Earnings Report

TuHURA Biosciences logo
$3.18 -0.03 (-0.93%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$3.20 +0.01 (+0.47%)
As of 05/29/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TuHURA Biosciences EPS Results

Actual EPS
-$68.18
Consensus EPS
-$6.29
Beat/Miss
Missed by -$61.89
One Year Ago EPS
N/A

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

TuHURA Biosciences Earnings Headlines

Zacks Small Cap Issues Pessimistic Outlook for HURA Earnings
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
Research Analysts Offer Predictions for HURA FY2027 Earnings
What is HC Wainwright's Forecast for HURA FY2025 Earnings?
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA), Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

View TuHURA Biosciences Profile

More Earnings Resources from MarketBeat